In 2014, Fresenius Kabi established UCN to raise awareness for disease-related malnutrition around the world. Through regional data collection and clinical assessment, and tailored events and tools for healthcare professionals, UCN aims to reduce the prevalence of hospital malnutrition. In 2018, the initiative expanded in Asia. To learn more, visit www.unitedforclinicalnutrition.com.
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, we focus on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell technologies, Fresenius Kabi offers products for collection and processing of blood and cell components.
With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
Authors: Fresenius Kabi Deutschland GmbH